cabotegravir
Transitions From Daily Dovato to Long-Acting Cabenuva Wanted by Patients With HIV
Many people with HIV want to transition from viral suppression with daily oral Dovato to long-acting injectable ...
JULY 23, 2025
Data Shows Preference for CAB-LA PrEP Without Straining Clinics
Two studies presented at IAS 2025 demonstrated the acceptability and feasibility of using Apretude for PrEP in ...
JULY 22, 2025
Key Takeaways for PrEP, HIV Treatment and Other Infectious Diseases
CROI 2025 highlighted promising therapeutic modalities for HIV treatment and prevention.
JULY 9, 2025
Cabenuva Implementation Successful in a Variety of HIV Clinics
Health care teams from a variety of HIV clinics in the United States reported that optimal implementation of ...
JULY 22, 2021
FDA Approves Cabenuva Long-Acting HIV Treatment
cabotegravir plus rilpivirine is dosed once monthly as an option to replace a patient’s current ...
JANUARY 22, 2021
Long-Acting Injectable More Effective Than Daily PrEP for Women
The investigational integrates inhibitor, cabotegravir, demonstrated superiority when compared with the current ...
NOVEMBER 10, 2020
FDA Declines Approval for Cabotegravir-Rilpivirine Long-Acting Combo for HIV
The long-acting injectable received a complete response letter due to chemistry manufacturing and controls. Viiv ...
DECEMBER 23, 2019
Janssen, ViiV Healthcare Collaborate on HIV Regimen Study
A two-drug combination of cabotegravir and rilpivirine is being studied for HIV.
JANUARY 19, 2016
